search
Back to results

A Study to Assess the Effect of a Probiotic on Upper Respiratory Tract Infections in Healthy Children (KLEENEX)

Primary Purpose

Upper Respiratory Tract Infections, Upper Resp Tract Infection

Status
Recruiting
Phase
Not Applicable
Locations
Ireland
Study Type
Interventional
Intervention
Probiotic
Placebo
Sponsored by
The Archer-Daniels-Midland Company
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional prevention trial for Upper Respiratory Tract Infections focused on measuring probiotic, microbiome

Eligibility Criteria

2 Years - 8 Years (Child)All SexesAccepts Healthy Volunteers

Inclusion Criteria:

  1. Have a parent/guardian able to give written informed consent.
  2. If ≥7 years, be able to give written informed assent.
  3. Healthy children aged 2 - 8 years old.
  4. In general good health, as determined by the investigator.
  5. Attending a registered childcare provider or school.
  6. Willing to consume the study product daily for the duration of the study.

Exclusion Criteria:

  1. Has URTI symptoms at the time of randomisation.
  2. Are <2 or ≥9 years old.
  3. Diagnosed with concomitant chronic infections, chronic systemic diseases, autoimmune diseases (e.g. asthma - generally only formally diagnosed after child is 6 years), immunodeficiency, metabolic diseases, chronic respiratory tract diseases including respiratory allergies and cystic fibrosis or congenital cardiac defects.
  4. Has a family household member that smokes cigarettes in the home.
  5. Has taken antibiotics within the previous 2 weeks prior to randomisation.
  6. Has taken probiotic supplements within the previous 2 weeks prior to randomisation
  7. Daily intake of immune stimulating products, including but not limited to echinacea, vitamin C and zinc in the 2 weeks before randomisation (multivitamins allowed).
  8. Has any significant health conditions that would prevent them from fulfilling the study requirements, put the Participant at risk or would confound the interpretation of the study results as judged by the investigator on the basis of medical history and routine laboratory test results.
  9. Taking a medication that the investigator believes would interfere with the objectives of the study or pose a safety risk or confound the interpretation of the study results.
  10. Has an active gastrointestinal disorder or previous gastrointestinal surgery (appendicectomy allowed).
  11. Has a gastrointestinal or chronic infective disease (i.e., coeliac disease, diarrhoea, Crohn's disease, ulcerative colitis, irritable bowel syndrome, diverticulosis, stomach or duodenal ulcers, hepatitis, HIV, cancer, etc.), or with a history of such diseases.
  12. Planned extensive travel (for >1 month) during the study duration.
  13. Parent/guardian who, in the opinion of the investigator, are considered to be poor attendees or unlikely for any reason to be able to comply with the study.
  14. Participants may not be receiving treatment involving experimental drugs. If the Participant has been in a recent experimental trial/study, these must have been completed not less than 60 days prior to this study.
  15. Any Participant who is the child of an employee of the study site or an Atlantia Clinical Trials employee or their close family member or a member of their household.

Sites / Locations

  • Atlantia Food Clinical TrialsRecruiting

Arms of the Study

Arm 1

Arm 2

Arm Type

Experimental

Placebo Comparator

Arm Label

Active

Placebo

Arm Description

Arm receiving investigational product (probiotic)

Arm receiving placebo

Outcomes

Primary Outcome Measures

Effect of 26 week consumption of probiotic on the total number of days that, otherwise healthy, children suffer from upper respiratory tract infection (URTI)
Presence of an URTI defined by a score of >2 on the Jackson Cold Scale (maximum score 3) where a lower score means better outcomes compared to baseline

Secondary Outcome Measures

Effect of 26 week consumption of probiotic on the number of children reporting at least one URTI
The presence of an URTI defined by a score of >2 on the Jackson Cold Scale (maximum score 3) where a lower score means better outcomes compared to baseline
Effect of 26 week consumption of probiotic on the average duration of URTIs reported by participants
Duration of URTI measured through the WURSS-K questionnaire (Maximum score 42) where a lower score means better outcomes compared to baseline
Effect of 26 week consumption of probiotic on the severity of URTI-related symptoms reported by participants
Severity of URTI measured through the WURSS-K questionnaire (Maximum score 42) where a lower score means better outcomes compared to baseline
Effect of 26 week consumption of probiotic on the total number of reported missed days of school/childcare due to illness
Recorded through the WURSS-K questionnaire (Maximum score 42) where a lower score means better outcomes compared to baseline
Effect of 26 week consumption of probiotic on the reported incidence of antibiotic use
Recorded through the WURSS-K questionnaire (Maximum score 42) where a lower score means better outcomes compared to baseline
Effect of 26 week consumption of probiotic on Salivary Immunoglobulin A levels (IgA) (mg/dL)
Measured via saliva sample
Effect of 26 week consumption of probiotic on the incidence of gastrointestinal infections
Recorded through the WURSS-K questionnaire (Maximum score 42) where a lower score means better outcomes compared to baseline

Full Information

First Posted
September 29, 2022
Last Updated
July 19, 2023
Sponsor
The Archer-Daniels-Midland Company
Collaborators
Atlantia Food Clinical Trials
search

1. Study Identification

Unique Protocol Identification Number
NCT05577065
Brief Title
A Study to Assess the Effect of a Probiotic on Upper Respiratory Tract Infections in Healthy Children
Acronym
KLEENEX
Official Title
A Randomised, Double-blinded, Placebo-controlled, Parallel Study, to Assess the Effect of a Probiotic on the Incidence, Duration and Severity of Upper Respiratory Tract Infections in Healthy Children
Study Type
Interventional

2. Study Status

Record Verification Date
July 2023
Overall Recruitment Status
Recruiting
Study Start Date
January 30, 2023 (Actual)
Primary Completion Date
November 2023 (Anticipated)
Study Completion Date
November 2023 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
The Archer-Daniels-Midland Company
Collaborators
Atlantia Food Clinical Trials

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
No

5. Study Description

Brief Summary
This study evaluates the efficacy of a single strain probiotic on the incidence, duration and severity of upper respiratory tract infections in healthy, school-age children.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Upper Respiratory Tract Infections, Upper Resp Tract Infection
Keywords
probiotic, microbiome

7. Study Design

Primary Purpose
Prevention
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Model Description
study consists of 2 arms, intervention and placebo.
Masking
ParticipantCare ProviderInvestigatorOutcomes Assessor
Allocation
Randomized
Enrollment
200 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
Active
Arm Type
Experimental
Arm Description
Arm receiving investigational product (probiotic)
Arm Title
Placebo
Arm Type
Placebo Comparator
Arm Description
Arm receiving placebo
Intervention Type
Dietary Supplement
Intervention Name(s)
Probiotic
Intervention Description
Single strain probiotic in the form of a sachet with a daily dose of 3E+9 Colony Forming Unit (CFU) per day for 26 weeks.
Intervention Type
Dietary Supplement
Intervention Name(s)
Placebo
Intervention Description
Matching placebo in the form of a sachet once daily for 26 weeks
Primary Outcome Measure Information:
Title
Effect of 26 week consumption of probiotic on the total number of days that, otherwise healthy, children suffer from upper respiratory tract infection (URTI)
Description
Presence of an URTI defined by a score of >2 on the Jackson Cold Scale (maximum score 3) where a lower score means better outcomes compared to baseline
Time Frame
Entire follow up period (total of 180 days)
Secondary Outcome Measure Information:
Title
Effect of 26 week consumption of probiotic on the number of children reporting at least one URTI
Description
The presence of an URTI defined by a score of >2 on the Jackson Cold Scale (maximum score 3) where a lower score means better outcomes compared to baseline
Time Frame
Day 0, Day 90, Day 180
Title
Effect of 26 week consumption of probiotic on the average duration of URTIs reported by participants
Description
Duration of URTI measured through the WURSS-K questionnaire (Maximum score 42) where a lower score means better outcomes compared to baseline
Time Frame
Day 0, Day 90, Day 180
Title
Effect of 26 week consumption of probiotic on the severity of URTI-related symptoms reported by participants
Description
Severity of URTI measured through the WURSS-K questionnaire (Maximum score 42) where a lower score means better outcomes compared to baseline
Time Frame
Day 0, Day 90, Day 180
Title
Effect of 26 week consumption of probiotic on the total number of reported missed days of school/childcare due to illness
Description
Recorded through the WURSS-K questionnaire (Maximum score 42) where a lower score means better outcomes compared to baseline
Time Frame
Day 0, Day 90, Day 180
Title
Effect of 26 week consumption of probiotic on the reported incidence of antibiotic use
Description
Recorded through the WURSS-K questionnaire (Maximum score 42) where a lower score means better outcomes compared to baseline
Time Frame
Day 0, Day 90, Day 180
Title
Effect of 26 week consumption of probiotic on Salivary Immunoglobulin A levels (IgA) (mg/dL)
Description
Measured via saliva sample
Time Frame
Day 0, Day 180
Title
Effect of 26 week consumption of probiotic on the incidence of gastrointestinal infections
Description
Recorded through the WURSS-K questionnaire (Maximum score 42) where a lower score means better outcomes compared to baseline
Time Frame
Day 0, Day 90, Day 180
Other Pre-specified Outcome Measures:
Title
Faecal Microbiome analysis
Description
Shallow shotgun metagenomic sequencing for 20% of cohort
Time Frame
Day 0, Day 180

10. Eligibility

Sex
All
Minimum Age & Unit of Time
2 Years
Maximum Age & Unit of Time
8 Years
Accepts Healthy Volunteers
Accepts Healthy Volunteers
Eligibility Criteria
Inclusion Criteria: Have a parent/guardian able to give written informed consent. If ≥7 years, be able to give written informed assent. Healthy children aged 2 - 8 years old. In general good health, as determined by the investigator. Attending a registered childcare provider or school. Willing to consume the study product daily for the duration of the study. Exclusion Criteria: Has URTI symptoms at the time of randomisation. Are <2 or ≥9 years old. Diagnosed with concomitant chronic infections, chronic systemic diseases, autoimmune diseases (e.g. asthma - generally only formally diagnosed after child is 6 years), immunodeficiency, metabolic diseases, chronic respiratory tract diseases including respiratory allergies and cystic fibrosis or congenital cardiac defects. Has a family household member that smokes cigarettes in the home. Has taken antibiotics within the previous 2 weeks prior to randomisation. Has taken probiotic supplements within the previous 2 weeks prior to randomisation Daily intake of immune stimulating products, including but not limited to echinacea, vitamin C and zinc in the 2 weeks before randomisation (multivitamins allowed). Has any significant health conditions that would prevent them from fulfilling the study requirements, put the Participant at risk or would confound the interpretation of the study results as judged by the investigator on the basis of medical history and routine laboratory test results. Taking a medication that the investigator believes would interfere with the objectives of the study or pose a safety risk or confound the interpretation of the study results. Has an active gastrointestinal disorder or previous gastrointestinal surgery (appendicectomy allowed). Has a gastrointestinal or chronic infective disease (i.e., coeliac disease, diarrhoea, Crohn's disease, ulcerative colitis, irritable bowel syndrome, diverticulosis, stomach or duodenal ulcers, hepatitis, HIV, cancer, etc.), or with a history of such diseases. Planned extensive travel (for >1 month) during the study duration. Parent/guardian who, in the opinion of the investigator, are considered to be poor attendees or unlikely for any reason to be able to comply with the study. Participants may not be receiving treatment involving experimental drugs. If the Participant has been in a recent experimental trial/study, these must have been completed not less than 60 days prior to this study. Any Participant who is the child of an employee of the study site or an Atlantia Clinical Trials employee or their close family member or a member of their household.
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
ADM Medical Team
Phone
+44 1460 243 230
Email
medical@protexin.com
First Name & Middle Initial & Last Name or Official Title & Degree
Atlantia Clinical Trials
Phone
+353 21 430 7442
Email
nring@atlantiatrials.com
Facility Information:
Facility Name
Atlantia Food Clinical Trials
City
Cork
ZIP/Postal Code
T23 R50R
Country
Ireland
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Niamh Ring
Phone
+353 21 430 7442
Email
nring@atlantiatrials.com

12. IPD Sharing Statement

Plan to Share IPD
No

Learn more about this trial

A Study to Assess the Effect of a Probiotic on Upper Respiratory Tract Infections in Healthy Children

We'll reach out to this number within 24 hrs